Tumorigenesis of colorectal cancer cells (CT26, red) were significantly reduced...
Tumorigenesis of colorectal cancer cells (CT26, red) were significantly reduced in mice liver tissue lacking IL-6 (Il6-/-), suggesting IL-6’s supportive function on metastasis.

Image source: Toyoshima Y. et al., Cancer Immunology Research 2019

Promising treatment target

"Partner-in-crime" of colorectal cancer discovered

A protein that helps colorectal cancer cells spread to other parts of the body could be an effective treatment target, researchers from Hokkaido University discovered.

Colorectal cancer patients with an immune system-regulating protein called interleukin 6 (IL-6) are more likely to have recurring tumors that can also spread to the liver, according to research published in the journal Cancer Immunology Research. The Hokkaido University investigations into the protein’s role in liver metastasis could help improve colorectal cancer treatment options. Colorectal cancer is the second most common cancer in women and third most common in men. The spreading of this cancer to other organs, most often to the liver, significantly reduces patient survival.

portrait of hidemitsu kitamura
Hidemitsu Kitamura of the Hokkaido University’s Institute for Genetic Medicine.
Source: Hokkaido University

One cancer treatment approach is immune therapy, which stimulates a person’s own immune system to attack tumor sites. However, its effectiveness varies with different cancers and in different people. This suggests that several different mechanisms are working at the same time to suppress the immune systems of those with cancer. Scientists are seeking ways to improve the effectiveness of immune therapy for patients.

Immunologist Hidemitsu Kitamura and colleagues at Japan’s Hokkaido University had previously found IL-6 expression plays a role in suppressing immune response in tumor tissues. They wanted to see if it also helps spread colorectal cancer to the liver. To do this, they used two groups of mice, one in which IL-6 expression was turned off and the other with IL-6 expression turned on. Both groups were inoculated with colorectal cancer cells. They assessed cancer levels in the liver, as well as the effects of IL-6 on different types of immune cells. They also analyzed IL-6 expression in human colorectal cancer patients.

“We hope that targeting IL-6 will be an effective approach to reduce the spread of cancer and improve survival in colorectal cancer patients. This approach could be combined with other immune therapy strategies, such as the one targeting PD-L1, to augment their effects on colorectal cancer in the future,” says Hidemitsu Kitamura.


Source: Hokkaido University

21.02.2020

Read all latest stories

Related articles

Photo

Chemotherapeutic delivery

Bowel cancer: Nanotechnology offers new hope

Bowel cancer survival rates could be improved if chemotherapy drugs were delivered via tiny nanoparticles to the diseased organs rather than oral treatment. That’s the finding from Indian and…

Photo

Stopping the spread

Research sheds new light on pancreatic cancer metastasis

With an overall survival rate of 9% for those diagnosed, pancreatic cancer remains exceedingly difficult to treat. However, the patient's primary tumor typically isn't what leads to death - it is the…

Photo

Mitochondria research

Colorectal cancer: Mutations in overlooked DNA could have huge impact on survival

DNA errors in the cell’s energy ‘factories’ increases the chances of survival for people with bowel cancer, also known as colorectal cancer, according to a new study. Studying how DNA errors…

Related products

Creative Biosciences - Colosafe

Creative Biosciences - Colosafe

Creative Biosciences (Guangzhou) Co., Ltd.
Sarstedt – Low DNA Binding Micro Tubes

Research Use Only (RUO)

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030

Research Use Only (RUO)

Shimadzu – CLAM-2030

Shimadzu Europa GmbH
Subscribe to Newsletter